PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C07D 209/42, 401/06, 401/12, A61K 31/40, 31/44, A61P 29/00

A1

(11) International Publication Number: WO 00/46196

(43) International Publication Date: 10 August 2000 (10.08.00)

(21) International Application Number: PCT/GB00/00265

(22) International Filing Date: 31 January 2000 (31.01.00)

(30) Priority Data:
9902461.4 5 February 1999 (05.02.99) GB

(71) Applicant *(for all designated States except US)*: ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).


(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: FAULL, Alan, Wellington [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). KETTLE, Jason, Grant [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: BRYANT, Tracey; Global Intellectual Property, AstraZeneca UK Limited, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS



(I)

(57) Abstract

A compound of formula (I) wherein R1 is hydrogen, halo or methoxy; R2 is hydrogen, halo, methyl, ethyl or methoxy; R3 is carboxy, tetrazolyl, or $-CONHSO_2R^4$ where R^4 is methyl, ethyl, phenyl, 2,5-dimethylisoxazolyl or trifluoromethyl; T is $-CH_2-$ or $-SO_2-$; and ring A is 3-chlorophenyl, 4-chlorophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl; or a pharmaceutically acceptable salt or prodrug thereof, as well as pharmaceutical compositions containing them are described and claimed. These compounds and compositions are useful in the treatment of disease mediated by monocyte chemoattractant protein-1 or RANTES (Regulated Upon Activation, Normal T-cell Expressed and Secreted), such as inflammatory disease.